Pilocarpine

AGN-190584 met the FDA’s high bar for safety and efficacy endpoints in the phase 3 GEMINI study.

LAS VEGAS — In this Healio Video Perspective from the ASCRS meeting, Eric D. Donnenfeld, MD, discusses topical presbyopia therapies, including pupillary constrictors and lens-softening vehicles.

Nyxol in combination with low-dose pilocarpine successfully met primary and key secondary endpoints in a phase 2 trial evaluating its safety and efficacy for presbyopia, according to a press release from Ocuphire Pharma.

ORLANDO – Use of Eyenovia’s MicroLine resulted in a three-line or more improvement in distance corrected near visual acuity in a statistically significant proportion of study subjects, according to a company representative.

MicroLine achieved the primary endpoint in the phase 3 VISION-1 clinical study, demonstrating temporary improvement of near vision in adults with presbyopia, according to a press release from Eyenovia.

Allergan has submitted a new drug application for its investigational presbyopia treatment and expects action on the NDA from the FDA by the end of the year.

Ocuphire Pharma has enrolled the first patients in a phase 2 proof of concept trial evaluating a combination of Nyxol and pilocarpine for the treatment of presbyopia, according to a press release.

Hickory Dickory Dock, a well-known nursery rhyme, is a nonsense poem in which children mimic the sound of a clock chiming at the relevant point in the song, intending to introduce the fundamentals of telling time.

Positive 1-year results for a fluid-optic IOL and potential benefits of violet lights filters lead recent refractive surgery coverage.

The FDA has accepted an investigational new drug application for Eyenovia’s MicroLine intended for symptomatic treatment of near vision due to presbyopia, according to a press release.